

# Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence

Information for the public  
Published: 10 August 2022

[www.nice.org.uk](http://www.nice.org.uk)

Nivolumab (Opdivo) is available on the NHS. It is a possible adjuvant treatment for muscle-invasive urothelial cancer that is at high risk of recurrence after radical resection (surgery) in adults if:

- their tumours express a protein called PD-L1 at a level of 1% or more and
- adjuvant treatment with platinum-based chemotherapy is unsuitable.

Adjuvant treatment aims to reduce the risk of the cancer coming back after surgery.

If you are not eligible for nivolumab but are already having it, you should be able to continue until you and your doctor decide when best to stop.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Action Bladder Cancer UK](#), 0300 302 0085
- [Fight Bladder Cancer](#), 01844 351621
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000.

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-4713-3